$4.20+0.07 (+1.69%)
LifeMD, Inc.
LifeMD, Inc. in the Healthcare sector is trading at $4.20 with a market capitalization of $242M. Wall Street consensus targets $9.88 (8 analysts), implying a +135.1% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 4.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $50.16M↑ | $7.08M↓ | $60.17M↓ | $62.22M↑ | $50.89M |
| Gross Profit | $44.24M↑ | $2.85M↓ | $52.76M↓ | $54.79M↑ | $42.75M |
| Operating Income | -$8.93M↓ | -$6.22M↓ | -$1.97M↓ | -$906,772↑ | -$1.18M |
| Net Income | -$8.87M↓ | $19.96M↑ | -$3.81M↓ | -$2.07M↓ | -$183,778 |
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platf...
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LifeMD’s latest analyst update comes with no change to the current price target, keeping expectations steady for now. Even without fresh commentary, the unchanged target still sends a signal about how analysts are holding their view. Looking ahead, you will see how to track these kinds of shifts so you can stay in step with the evolving LifeMD story. Stay updated as the Fair Value for LifeMD shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover...
The United States market has shown a positive trend, with a 1.3% increase over the last week and a 28% rise over the past year, alongside an anticipated annual earnings growth of 17%. Investing in penny stocks — once considered more mainstream but now seen as niche — can still offer access to potential growth opportunities, particularly in smaller or newer companies. We've identified three penny stocks that demonstrate strong financial health and long-term potential, offering investors a...
Moby summary of LifeMD, Inc.'s Q1 2026 earnings call
LifeMD (NASDAQ:LFMD) reported first-quarter 2026 results that management said marked a strong start to the year, highlighted by revenue that topped guidance and record subscriber growth as the company continued shifting its weight management business toward branded GLP-1 therapies and expanded insur